MyFinsight
Home
Blog
About
Contact
Download
Download image
Affitech Research
As-Vabysmo
$23,957K
Ladrx-Miplyffa
$1,799K
Aptevo-Ixinity
$989K
Tovorafenib-Viracta Therapeutics
Inc.
$13,716K
Dsuvia-Talphera
$28K
Income from purchased
receivables under the eir...
$26,745K
Income from purchased
receivables under the cost...
$13,744K
Revenue from contracts
with customers
$10,350K
Revenue recognized
under...
$1,310K
Total income and
revenues
$52,149K
Gains on acquisitions
$21,224K
Other income, net
$12,238K
Income (loss) from
operations
$11,384K
Total operating
expenses
$40,765K
Net income (loss)
before tax
$31,815K
Interest expense
$13,031K
General and
administrative
$36,092K
Amortization of intangible
assets
$2,961K
Research and development
$1,712K
Net income (loss)
$31,712K
Income tax (expense)
benefit
$103K
Bargain purchase gain
$4,457K
Changes in valuation
allowances
-$2,538K
Stock based
compensation
-$584K
U.s. federal
statutory tax rate
$6,681K
Nondeductible executive
compensation
$735K
Other permanent
differences
$163K
Foreign tax effects
$103K
Back
Back
Income Statement
source: myfinsight.com
XOMA Royalty Corp (XOMA)
XOMA Royalty Corp (XOMA)